Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.6 GBX | +9.45% | +7.83% | -33.64% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
May. 02 | Capita CFO to Retire in August; Successor Named | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.31 for the 2024 fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Business Support Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.64% | 309M | C+ | ||
+16.20% | 71.05B | B+ | ||
+7.27% | 17.43B | B+ | ||
+14.34% | 13.99B | B- | ||
+23.04% | 13.75B | A- | ||
+17.76% | 10.09B | B- | ||
-22.30% | 6.71B | C | ||
-4.35% | 5.98B | A- | ||
+1.07% | 5.15B | B- | ||
-0.71% | 4.98B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CPI Stock
- Ratings Capita plc